NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE201697 Query DataSets for GSE201697
Status Public on Apr 28, 2022
Title miR-200c-3p, miR-222-5p and miR-512-3p are outcome circulating biomarkers in patients with hepatocarcinoma under Sorafenib treatment
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Other
Summary This SuperSeries is composed of the SubSeries listed below.
 
Overall design Refer to individual Series
 
Citation(s) 36078082
Submission date Apr 27, 2022
Last update date Sep 15, 2022
Contact name Patricia de la Cruz-Ojeda
Organization name Institute of Biomedicine of Seville
Lab 209
Street address Avda. Manuel Siurot s/n
City Sevilla
ZIP/Postal code 41011
Country Spain
 
Platforms (2)
GPL30173 NextSeq 2000 (Homo sapiens)
GPL32217 ThermoFisher TaqMan™ OpenArray™ Human MicroRNA Panel, QuantStudio™ 12K Flex (Catalog number: 4470187)
Samples (48)
GSM6069610 IC_6h_control_1
GSM6069611 IC_6h_control_2
GSM6069612 IC_6h_control_3
This SuperSeries is composed of the following SubSeries:
GSE201695 Transcriptomic analysis of hepatocellular carcinoma cell lines HepG2 treated with Sorafenib and transfected with miR-200c-3p inhibitor, and miR-222-5p and miR-512-3p mimics
GSE201696 miRNA expression induced by Sorafenib in HepG2 cells and primary human hepatocytes
Relations
BioProject PRJNA832689

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE201697_RAW.tar 130.0 Kb (http)(custom) TAR (of TXT)
SRA Run SelectorHelp

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap